A Phase 3 interventional study of zilucoplan (RA101495) and Placebo in Myasthenia Gravis, Generalized, sponsored by Ra Pharmaceuticals, Inc.. Completed at 77 sites in 10 countries. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-07-16.
Sponsored by Ra Pharmaceuticals, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Myasthenia Gravis by UCB S.A. — 5 open to participants now, 7 under way, 5 of them phase 3. Myasthenia Gravis · UCB S.A..
Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 3rd largest by enrollment, is one of 4 that started in 2019, is one of 12 in phase 3, and was the 4th registered.
331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →5 of the 18 studies in Myasthenia Gravis by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, China and 6 more countries
Ages 18+
Candid Therapeutics · Sites in China
Ages 18+
UCB Biopharma SRL · Sites in United States, Italy, Poland and 2 more countries
Ages 12–17
UCB Biopharma SRL · Sites in Italy, Poland, Korea, Republic of and 1 more country
Ages 12+
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 14 · Phase 4 1
First in 2017; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 174 is above the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 45 across the 18 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Ra Pharmaceuticals, Inc., one of the names counted as UCB S.A.. Under that name alone:
Ra Pharmaceuticals, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
4 of the studies in Myasthenia Gravis by UCB S.A. that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06055959Phase 3UCB Biopharma SRLA Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | 2027-05-12 |
| NCT06540144Phase 3UCB Biopharma SRLAn Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | 2027-10-05 |
| NCT06435312Phase 3UCB Biopharma SRLAn Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | 2027-10-26 |
| NCT07246564UCB Biopharma SRLPhase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | 2027-10-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Myasthenia Gravis by UCB S.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The RAISE study is a multicenter, randomized, double-blind, placebo controlled study to confirm the efficacy, safety, and tolerability of zilucoplan in subjects with generalized Myasthenia Gravis. Subjects will be randomized in a 1:1 ratio to receive daily SC doses of 0.3 mg/kg zilucoplan or placebo for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: zilucoplan (RA101495)
Drug: Placebo
Daily subcutaneous (SC) injection
Daily subcutaneous (SC) injection
Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score
The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. A decrease from Baseline score indicated improvement.
Time frame: From Baseline to End of Treatment (Week 12)
Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Total Score
The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consisted of 13 items. Each item in the scale scored on a 0 to 3-point scale, ranging from 0 (no weakness) to 3 (severe weakness), summing up to the overall score range from 0 to 39. Higher scores indicated more severe impairment. A decrease from Baseline score indicated improvement.
Time frame: From Baseline to End of Treatment (Week 12)
Change From Baseline to Week 12 in the Myasthenia Gravis Composite (MGC) Scale Total Score
The total MGC score was sum of responses to 10 individual items : 1. Ptosis upward gaze (0 to 3), 2. Double vision on lateral gaze, left or right (0, to 4), 3. Eye closure (0 to 2), 4. Talking (0 to 6), 5. Chewing (0 to 6), 6. Swallowing \[0 to 6\], 7. Breathing (0 to 9), 8. Neck flexion or extension (0 to 4), 9. Shoulder abduction (0 to 5), 10. Hip flexion (0 to 5). The higher score for each item indicated severity. The total score ranged 0 to 50 with higher score indicative of severe disease activity). A decrease from Baseline score showed improvement.
Time frame: From Baseline to End of Treatment (Week 12)
Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life Revised (MG-QoL15r) Scale Total Score
The MG-QoL15r is a 15-item patient-reported outcome measure designed to assess quality of life in patients with MG. Each item in the scale scored on a 0 to 2-point scale (0=Not much at all, 1=Somewhat, 2=Very much). The total score was the sum of the 15 individual item scores, ranging from 0 to 30. Higher scores indicated more severe impact of the disease on aspects of the patient's life. A decrease from Baseline score indicated improvement.
Time frame: From Baseline to End of Treatment (Week 12)
Time to First Receipt of Rescue Therapy Over the 12-week Treatment Period
Time to first receipt of rescue therapy over the 12-week treatment period (in days) was defined as the date of first rescue therapy use minus date of first Investigational Medicinal Product (IMP) + 1.
Time frame: From Baseline to End of Treatment (Week 12)
Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 12 Without Rescue Therapy
Percentage of Participants achieving MSE was defined as achieving a MG-ADL value of a 0 (No MG symptoms) or 1 (Mild MG symptoms) at Week 12 and not having taken rescue therapy. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the missing at Random (MAR) assumption.
Time frame: End of Treatment (Week 12)
Percentage of Participants Achieving a ≥ 3-point Reduction in MG-ADL Score at Week 12 Without Rescue Therapy
Percentage of participants achieving a ≥ 3-point reduction in MG-ADL Score at Week 12 without rescue therapy were reported. The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored on a 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the MAR assumption.
Time frame: End of Treatment (Week 12)
Percentage of Participants Achieving a ≥5-point Reduction in QMG Score Without Rescue Therapy at Week 12
Percentage of participants achieving a ≥5-point reduction in QMG Score without rescue therapy at Week 12 were reported. The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consisted of 13 items. Each item in the scale scored on a 0 to 3-point scale, ranging from 0 (no weakness) to 3 (severe weakness), summing up to the overall score range from 0 to 39. Higher scores indicated more severe impairment. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the MAR assumption.
Time frame: End of Treatment (Week 12)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE is defined as an AE starting on or after the time of first administration of IMP and up to and including 40 days after the final dose (or last contact depending on which occurs first). Adverse events starting before the date of the first administration of IMP were not considered TEAEs.
Time frame: From Baseline (Day 1) to Safety Follow-up visit (19 Weeks [12 weeks Treatment Period plus up to 7 weeks Follow-up])
The study started to enroll participants in September 2019 and concluded in December 2021.
| Milestone | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Started | 88 | 86 |
| Completed | 84 | 82 |
| Not completed | 4 | 4 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Death | 1 | 1 |
The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. A decrease from Baseline score indicated improvement.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline (CFB) to Week 12 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Total Score | -2.30 (-3.17 to -1.43) | -4.39 (-5.28 to -3.50) |
The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consisted of 13 items. Each item in the scale scored on a 0 to 3-point scale, ranging from 0 (no weakness) to 3 (severe weakness), summing up to the overall score range from 0 to 39. Higher scores indicated more severe impairment. A decrease from Baseline score indicated improvement.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 12 in the Quantitative Myasthenia Gravis (QMG) Total Score | -3.25 (-4.32 to -2.17) | -6.19 (-7.29 to -5.08) |
The total MGC score was sum of responses to 10 individual items : 1. Ptosis upward gaze (0 to 3), 2. Double vision on lateral gaze, left or right (0, to 4), 3. Eye closure (0 to 2), 4. Talking (0 to 6), 5. Chewing (0 to 6), 6. Swallowing \[0 to 6\], 7. Breathing (0 to 9), 8. Neck flexion or extension (0 to 4), 9. Shoulder abduction (0 to 5), 10. Hip flexion (0 to 5). The higher score for each item indicated severity. The total score ranged 0 to 50 with higher score indicative of severe disease activity). A decrease from Baseline score showed improvement.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 12 in the Myasthenia Gravis Composite (MGC) Scale Total Score | -5.42 (-6.98 to -3.86) | -8.62 (-10.22 to -7.01) |
The MG-QoL15r is a 15-item patient-reported outcome measure designed to assess quality of life in patients with MG. Each item in the scale scored on a 0 to 2-point scale (0=Not much at all, 1=Somewhat, 2=Very much). The total score was the sum of the 15 individual item scores, ranging from 0 to 30. Higher scores indicated more severe impact of the disease on aspects of the patient's life. A decrease from Baseline score indicated improvement.
| score on a scale | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life Revised (MG-QoL15r) Scale Total Score | -3.16 (-4.65 to -1.67) | -5.65 (-7.17 to -4.12) |
Time to first receipt of rescue therapy over the 12-week treatment period (in days) was defined as the date of first rescue therapy use minus date of first Investigational Medicinal Product (IMP) + 1.
| Days | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Time to First Receipt of Rescue Therapy Over the 12-week Treatment Period | NA (NA to NA) | NA (NA to NA) |
Percentage of Participants achieving MSE was defined as achieving a MG-ADL value of a 0 (No MG symptoms) or 1 (Mild MG symptoms) at Week 12 and not having taken rescue therapy. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the missing at Random (MAR) assumption.
| percentage of participants | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Percentage of Participants Achieving Minimal Symptom Expression (MSE) at Week 12 Without Rescue Therapy | 5.8 | 14.0 |
Percentage of participants achieving a ≥ 3-point reduction in MG-ADL Score at Week 12 without rescue therapy were reported. The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale scored on a 0 to 3 (0=None, 3=severe disease) point scale. The total score was the sum of all individual item scores and ranged from 0 to 24. Higher scores indicated more severe disability due to MG. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the MAR assumption.
| percentage of participants | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Percentage of Participants Achieving a ≥ 3-point Reduction in MG-ADL Score at Week 12 Without Rescue Therapy | 46.1 | 73.1 |
Percentage of participants achieving a ≥5-point reduction in QMG Score without rescue therapy at Week 12 were reported. The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consisted of 13 items. Each item in the scale scored on a 0 to 3-point scale, ranging from 0 (no weakness) to 3 (severe weakness), summing up to the overall score range from 0 to 39. Higher scores indicated more severe impairment. Any participant with an event of death, myasthenic crisis or rescue therapy was considered as non-responders. Any other missing data was imputed using the MAR assumption.
| percentage of participants | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Percentage of Participants Achieving a ≥5-point Reduction in QMG Score Without Rescue Therapy at Week 12 | 33.0 | 58.0 |
A TEAE is defined as an AE starting on or after the time of first administration of IMP and up to and including 40 days after the final dose (or last contact depending on which occurs first). Adverse events starting before the date of the first administration of IMP were not considered TEAEs.
| percentage of participants | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) | 70.5 | 76.7 |
Collected over From Baseline (Day 1) to Safety follow-up visit (19 Weeks [12 weeks Treatment Period plus up to 7 weeks follow-up]). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/88 (1.1%) | 13/88 (14.8%) | 34/88 (38.6%) |
| Zilucoplan 0.3 mg/kg | 1/86 (1.2%) | 11/86 (12.8%) | 41/86 (47.7%) |
| Event | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Myasthenia gravisNervous system disorders | 5/88 | 2/86 |
| COVID-19Infections and infestations | 2/88 | 1/86 |
| COVID-19 pneumoniaInfections and infestations | 2/88 | 1/86 |
| AnaemiaBlood and lymphatic system disorders | 0/88 | 1/86 |
| Aphthous ulcerGastrointestinal disorders | 0/88 | 1/86 |
| Oesophageal candidiasisInfections and infestations | 0/88 | 1/86 |
| Oral candidiasisInfections and infestations | 0/88 | 1/86 |
| PneumoniaInfections and infestations | 0/88 | 1/86 |
| SepsisInfections and infestations | 0/88 | 1/86 |
| Lipase increasedInvestigations | 0/88 | 1/86 |
| Event | Placebo | Zilucoplan 0.3 mg/kg |
|---|---|---|
| Injection site bruisingGeneral disorders | 8/88 | 14/86 |
| HeadacheNervous system disorders | 14/88 | 13/86 |
| DiarrhoeaGastrointestinal disorders | 2/88 | 9/86 |
| Injection site painGeneral disorders | 3/88 | 8/86 |
| Myasthenia gravisNervous system disorders | 5/88 | 8/86 |
| Urinary tract infectionInfections and infestations | 4/88 | 7/86 |
| ContusionInjury, poisoning and procedural complications | 3/88 | 7/86 |
| Lipase increasedInvestigations | 1/88 | 6/86 |
| NasopharyngitisInfections and infestations | 3/88 | 5/86 |
| Amylase increasedInvestigations | 2/88 | 5/86 |
The modified Intention-to-Treat (mITT) population included all randomized participants who received at least 1 dose of study drug and had at least 1 post-dosing MG-ADL score.
| Age, Categorical(Participants) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 62 | 64 | 126 |
| >=65 years | 26 | 22 | 48 |
| Age, Continuous(years) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| Mean | 53.3 ± 15.7 | 52.6 ± 14.6 | 53.0 ± 15.1 |
| Sex: Female, Male(Participants) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| Female | 47 | 52 | 99 |
| Male | 41 | 34 | 75 |
| Race/Ethnicity, Customized(Participants) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| American Indian/Alaska native | 1 | 0 | 1 |
| Asian | 14 | 7 | 21 |
| Black | 7 | 6 | 13 |
| Native Hawaiian or other Pacific Islander | 0 | 0 | 0 |
| White | 62 | 66 | 128 |
| Other/Mixed | 0 | 0 | 0 |
| Missing | 4 | 7 | 11 |
| Race/Ethnicity, Customized(Participants) | Placebo | Zilucoplan 0.3 mg/kg | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 7 | 12 |
| Not Hispanic or Latino | 79 | 72 | 151 |
| Missing | 4 | 7 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed;in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Sep 2019 to primary completion in Dec 2021, 27 months.
Results were first posted in Jan 2023, 1 year after primary completion.
Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 27 months is close to that.
Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilucoplan